Skip to content

Clinical trials

Phase 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Phase: Phase 1 Country / region: China Clear all

59 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20151
20163
20171
201910
202012
20215
202210
20235
20246
20252
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status29
Recruiting14
Completed7
Withdrawn2
Not yet recruiting2
Terminated2
Active, not recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Zhejiang University5
Institute of Hematology & Blood Diseases Hospital, China4
Beijing Boren Hospital3
Chongqing Precision Biotech Co., Ltd3
He Huang3
PersonGen BioTherapeutics (Suzhou) Co., Ltd.3
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology3
Hebei Senlang Biotechnology Inc., Ltd.2
Hrain Biotechnology Co., Ltd.2
Kai Lin Xu; Jun Nian Zheng2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma59
Lymphoma, Non-Hodgkin16
Leukemia8
Lymphoma, B-Cell8
Recurrence8
Leukemia, Lymphocytic, Chronic, B-Cell7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma4
Burkitt Lymphoma3
Leukemia, Myeloid, Acute3
Lymphoma2

Trials

Showing 1 to 25 of 59. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.